A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Patients will be enrolled in two groups. Group 1 will enroll patients who are not candidates
for surgery. Group 2 will enroll patients who are surgical candidates. Patients from both
groups will be evaluated for tumor response and progression by MRI every 8 weeks until
disease progression or discontinuation from study using RANO criteria.

Inclusion criteria:

1. Patients with histologically confirmed GBM and/or other glioma subtypes at the time of
diagnosis or prior relapse.

2. Written documentation of local or central laboratory determination of amplification or
translocation to FGFR1-TACC1, FGFR3-TACC-3 fusion and/or activating mutation in FGFR1,
FGFR2,or FGFR3

3. RANO defined tumor progression by MRI in comparison to a prior scan

4. Patients must have received prior external beam radiotherapy and temozolomide.

Exclusion criteria:

1. History of another primary malignancy

2. Prior or current treatment with a FGFR inhibitor

3. Neurological symptoms related to underlying disease requiring increasing doses of
corticosteroids

4. Patients must not be taking Enzyme Inducing Anti-Epileptic Drug (EIAED). If previously
on an EIAED, the patient must be off of it for at least two weeks prior to study
treatment.